EP Patent

EP0929576A1 — Glp-2 derivatives

Assigned to Novo Nordisk AS · Expires 1999-07-21 · 27y expired

What this patent protects

Derivatives of hGLP-2 and analogues thereof and fragments thereof and analogues of such fragments having a lipophilic substituent have interesting pharmacological properties, in particular they have a more protracted profile of action than the parent peptides.

USPTO Abstract

Derivatives of hGLP-2 and analogues thereof and fragments thereof and analogues of such fragments having a lipophilic substituent have interesting pharmacological properties, in particular they have a more protracted profile of action than the parent peptides.

Drugs covered by this patent

Patent Metadata

Patent number
EP0929576A1
Jurisdiction
EP
Classification
—
Expires
1999-07-21
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.